IONS
Ionis Embarks on New Chapter as Fully Integrated Commercial Stage Biotech
In a recent conference call to discuss its 2024 Q4 financial results, Ionis Pharmaceuticals highlighted its transition into a fully integrated commercial stage biotechnology company. The company has kicked off this new chapter with the successful independent launch of TRYNGOLZA, a treatment for familial chylomicronemia syndrome (FCS), in adults. Brett